Skip to main content
Premium Trial:

Request an Annual Quote

Downloads and Upgrades: Cortellis Data Fusion, NCBI's Sequence Viewer, Accelrys' ScienceCloud, and more


This week, Thomson Reuters launched Cortellis Data Fusion, an addition to the company's Cortellis suite, which provides access to information for drug discovery and development.

According to the company, Cortellis Data Fusion — which incorporates tools from Thomson Reuters' acquisition of Entagen — uses linked data technologies to connect data from internal proprietary systems to third-party resources enabling users to discover associations in their data, generate hypotheses, and share ideas.

The National Center for Biotechnology Information has released an updated version its Sequence Viewer tool which offers improved compatibility with Internet Explorer for users embedding the resource on their web sites. It also offers improved performance and response time. Details about features included in this release are available here.

The NCBI has also released Entrez Direct, a new software suite that lets researchers use the Unix command line to directly access NCBI's data servers, as well as parse and format data to create customized data files. The software is available via ftp and details about the release can be found here.

Accelrys has launched ScienceCloud, a Software-as-a-Service-based information management and collaboration workspace. The new infrastructure supports drug discovery efforts by providing a set of integrated cloud-based applications for uploading, processing, storing, searching, and analyzing structured and unstructured scientific information including biology, chemistry, analytical, safety, and pharmacokinetics data.

The authors of the Structural Classification of Proteins (SCOP) database have released a beta version of a prototype of SCOP2.

According to the developers, SCOP2 defines a new approach to the protein classification that is fundamentally different from the old SCOP but retains its best features. They are seeking feedback from the community about the changes they've made.

Certara has launched its Phoenix QT+ Cardiac Safety Assessment tool, which provides data processing, statistical, and modeling capabilities for determining whether a drug candidate prolongs cardiac repolarization, a surrogate for potentially-fatal arrhythmias.